What healthcare interventions do IVI’s disease-specific models evaluate?

IVI’s disease-specific models currently focus on the relative value of drug therapies and do not include other types of intervention (surgery, for example). To model the relative efficacy of different treatments or interventions, we must first know how the various options compare to one another, which requires reliable clinical evidence from randomized control trials (RCTs). [...]

2019-01-31T11:59:33-05:00January 31st, 2019||

Are IVI’s disease-specific models developed with clinical input?

Yes! When beginning the development of a disease-specific OSVP model, IVI recruits a Clinical Scientific Advisor with relevant expertise to join the modeling team. Dr. Jeff Curtis, a rheumatologist and professor at the University of Alabama Birmingham, serves in this capacity on the IVI-RA decision model. For the IVI-NSCLC decision model, this clinical expertise is [...]

2019-01-31T12:00:37-05:00January 31st, 2019||

How is real-world evidence used in IVI’s disease-specific models?

To ensure that simulated outcomes reflect outcomes in routine practice, baseline events rates (i.e., the rate of disease progression, the mortality rate, the rate at which patients discontinue treatment), patient preferences, and costs are modeled using real-world data. To enhance validity, relative treatment effects relative treatment effects (e.g., relative risks, odds ratios, and [...]

2019-01-31T12:01:52-05:00January 31st, 2019||

As a patient, can I contribute to future iterations of IVI’s models?

We aim to develop models that capture all aspects of value important to the patient. This starts with providing input on our disease-specific models, currently available for rheumatoid arthritis and EGFR+ non-small cell lung cancer. Any feedback you can provide during public comment periods for our models will be considered in modifying the existing versions [...]

2021-07-09T16:05:05-04:00January 31st, 2019||
Go to Top